Huntington disease

maze unravel find navigate direction path

uniQure's interim data shows gene therapy slows Huntington’s

uniQure’s Huntington’s disease trial got off to a bumpy start, but the slices of interim data released by the company continue to look more promising.

James Waldron Jul 9, 2024 9:25am

Sage's dalzanemdor trial design leaves efficacy question unclear

Jun 11, 2024 8:28am

VectorY raises $138M to push forward ALS program

Nov 13, 2023 10:26am

two ways to win two goals target arrow multiple

JPM23: Annexon looks for '2 ways to win' in Huntington's trial

Jan 11, 2023 12:55pm

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Dec 14, 2022 7:15am

UniQure set to resume dosing in open-label Huntington's trial

Nov 2, 2022 10:18am